Abstract
With increasing cost-containment pressures within healthcare systems worldwide, economic evaluations of medical technologies, particularly pharmaceuticals, are used to aid the allocation of expenditure and resources. Facing similar pressures, Japan will probably also introduce economic evaluation of health technology. However, the structure of the healthcare system in Japan does not lend itself naturally to the collection of the epidemiological and cost data required for economic evaluations in medicine. In addition, there are no formal methodological guidelines in place for these analyses. To overcome these information barriers in Japan, progress may be aided by the adoption of approaches used in other countries for data collection and guideline development.
| Original language | English |
|---|---|
| Pages (from-to) | 9-15 |
| Number of pages | 7 |
| Journal | PharmacoEconomics |
| Volume | 20 |
| Issue number | SUPPL. 2 |
| Publication status | Published - 2002 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology
- Medicine (miscellaneous)
Cite this
Information barriers to the implementation of economic evaluations in Japan. / Nishimura, Shuzo; Torrance, George W.; Ikegami, Naoki; Fukuhara, Shunichi; Drummond, Michael; Schubert, François.
In: PharmacoEconomics, Vol. 20, No. SUPPL. 2, 2002, p. 9-15.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Information barriers to the implementation of economic evaluations in Japan
AU - Nishimura, Shuzo
AU - Torrance, George W.
AU - Ikegami, Naoki
AU - Fukuhara, Shunichi
AU - Drummond, Michael
AU - Schubert, François
PY - 2002
Y1 - 2002
N2 - With increasing cost-containment pressures within healthcare systems worldwide, economic evaluations of medical technologies, particularly pharmaceuticals, are used to aid the allocation of expenditure and resources. Facing similar pressures, Japan will probably also introduce economic evaluation of health technology. However, the structure of the healthcare system in Japan does not lend itself naturally to the collection of the epidemiological and cost data required for economic evaluations in medicine. In addition, there are no formal methodological guidelines in place for these analyses. To overcome these information barriers in Japan, progress may be aided by the adoption of approaches used in other countries for data collection and guideline development.
AB - With increasing cost-containment pressures within healthcare systems worldwide, economic evaluations of medical technologies, particularly pharmaceuticals, are used to aid the allocation of expenditure and resources. Facing similar pressures, Japan will probably also introduce economic evaluation of health technology. However, the structure of the healthcare system in Japan does not lend itself naturally to the collection of the epidemiological and cost data required for economic evaluations in medicine. In addition, there are no formal methodological guidelines in place for these analyses. To overcome these information barriers in Japan, progress may be aided by the adoption of approaches used in other countries for data collection and guideline development.
UR - http://www.scopus.com/inward/record.url?scp=0036377674&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036377674&partnerID=8YFLogxK
M3 - Article
C2 - 12238944
AN - SCOPUS:0036377674
VL - 20
SP - 9
EP - 15
JO - PharmacoEconomics
JF - PharmacoEconomics
SN - 1170-7690
IS - SUPPL. 2
ER -